Caremo Recognized as "2023 Jiangsu Potential Unicorn Enterprise"

Recently, the Jiangsu Provincial Productivity Promotion Center released the "2023 Jiangsu Unicorn Enterprise Evaluation Results". Caremo was honored as a "2023 Jiangsu Potential Unicorn Enterprise" for its R&D innovation capabilities, core technological strengths, and rapid growth potential in the pharmaceutical industry.

Unicorn enterprises are pioneers in emerging fields and sectors, serving as key drivers of technological advancement. They are characterized by innovation, high potential, and high growth, with a focus on leading technological breakthroughs. The 2023 evaluation emphasized three criteria:

- High post-financing valuation and market recognition

- Mastery of core high-tech competencies and market-leading products

- Strong operational performance

This accolade recognizes Caremo’s technical expertise, professional excellence, innovative capacity, and exceptional growth trajectory, while affirming its market performance and strategic vision. Since its founding in June 2020, Caremo has adhered to its mission—"Born for Health, Empowered for Innovation"—by integrating core technologies to bridge innovative and generic drug development through a dual-drive strategy of R&D and industrialization. The company delivers customized R&D and industrialization solutions tailored to diverse client needs.

To date, Caremo has earned multiple certifications and honors, including:

- National High-Tech Enterprise

- Technology-based SME

- Jiangsu Provincial Private Technology Enterprise

- Jiangsu Potential Unicorn Enterprise

- Nanjing Municipal Special Dosage Form Drug Engineering Technology Research Center

- "2023 Most Competitive Pharmaceutical Service Enterprise in China"

- "2022-2023 Top 50 Chinese Pharmaceutical R&D Enterprises"

- "2023 Top 20 Chinese R&D CRO Enterprises"